Login to Your Account

Clovis Partners with Avila in $209M NSCLC Deal

By Donna Young

Wednesday, May 26, 2010
Clovis Oncology Inc. has landed a second oncology partnership in its first year of business, this time with Waltham, Mass.-based Avila Therapeutics Inc. to develop and commercialize epidermal growth factor receptor (EGFR) mutant-selective inhibitors (EMSI) to treat non-small-cell lung cancer (NSCLC) in a deal potentially worth $209 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription